The decision to start alectinib was based on the results of the ALEX study, which showed that the rate of investigator-assessed progression-free survival was significantly higher with alectinib than with crizotinib in treatment-naive ALK-positive NSCLC (20, 21). The gene discussed is ALK; the disease is non-small cell lung carcinoma.